CellSource Co (TSE:4880) Debt-to-Equity : 0.00 (As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CellSource Co Debt-to-Equity?

CellSource Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円0 Mil. CellSource Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円0 Mil. CellSource Co's Total Stockholders Equity for the quarter that ended in Jan. 2024 was 円5,961 Mil. CellSource Co's debt to equity for the quarter that ended in Jan. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CellSource Co's Debt-to-Equity or its related term are showing as below:

TSE:4880' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.02
Current: 0.02

During the past 7 years, the highest Debt-to-Equity Ratio of CellSource Co was 0.02. The lowest was 0.00. And the median was 0.01.

TSE:4880's Debt-to-Equity is ranked better than
87.78% of 1072 companies
in the Biotechnology industry
Industry Median: 0.14 vs TSE:4880: 0.02

CellSource Co Debt-to-Equity Historical Data

The historical data trend for CellSource Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellSource Co Debt-to-Equity Chart

CellSource Co Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.02

CellSource Co Quarterly Data
	Oct18	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	0.02	-

Competitive Comparison of CellSource Co's Debt-to-Equity

For the Biotechnology subindustry, CellSource Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CellSource Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CellSource Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CellSource Co's Debt-to-Equity falls into.

CellSource Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CellSource Co's Debt to Equity Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(20.251	+	77.291)	/	6201.997
	=	0.02

CellSource Co's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	5960.953
	=	0.00

CellSource Co (TSE:4880) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CellSource Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CellSource Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CellSource Co (TSE:4880) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CellSource Co Ltd (TSE:4880) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002

Website

https://www.cellsource.co.jp

CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.

CellSource Co (TSE:4880) Headlines

No Headlines